Ibrance 125 mg (Palbociclib) is an innovative targeted medication used to treat specific types of metastatic breast cancer. Palbociclib is a first-in-class inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). By blocking these proteins, the drug slows the division of tumor cells and prevents disease progression, significantly increasing progression-free survival when used in combination with hormonal therapy.
Manufacturer: Pfizer, USA. Ibrance has made a breakthrough in oncology, becoming a standard of therapy for patients with hormone-receptor-positive cancer, allowing for long-term disease control while maintaining quality of life.
Key Features:
- ✅ Cycle Control Mechanism: Selectively blocks the transition of cancer cells from the resting phase to the division phase.
- ✅ Synergy with Hormone Therapy: Enhances the effect of aromatase inhibitors and fulvestrant, overcoming tumor resistance.
- ✅ Convenience of Use: The oral form in a 125 mg dosage is the standard starting dose for most patients.